Insider Selling: Health Catalyst (NASDAQ:HCAT) General Counsel Sells $100,100.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) General Counsel Benjamin Landry sold 70,000 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $1.43, for a total value of $100,100.00. Following the transaction, the general counsel owned 281,372 shares of the company’s stock, valued at $402,361.96. The trade was a 19.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Benjamin Landry also recently made the following trade(s):

  • On Thursday, November 12th, Benjamin Landry sold 29,478 shares of Health Catalyst stock. The stock was sold at an average price of $1.39, for a total transaction of $40,974.42.

Health Catalyst Stock Performance

HCAT stock opened at $1.51 on Monday. Health Catalyst, Inc. has a 1-year low of $0.96 and a 1-year high of $3.02. The firm has a market cap of $114.99 million, a PE ratio of -0.53 and a beta of 1.52. The business’s 50-day moving average price is $1.69 and its two-hundred day moving average price is $1.68.

Health Catalyst (NASDAQ:HCAT – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The company had revenue of $56.28 million for the quarter, compared to analyst estimates of $55.39 million. Health Catalyst had a negative return on equity of 4.84% and a negative net margin of 74.24%. On average, analysts forecast that Health Catalyst, Inc. will post -0.18 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group cut shares of Health Catalyst from a “buy” rating to a “hold” rating and decreased their target price for the company from $3.00 to $1.80 in a research note on Thursday, August 20th. Citigroup reduced their price target on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Wells Fargo & Company cut their price objective on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a research report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Health Catalyst in a research note on Monday, October 26th. Five equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average price target of $2.01.

Read Our Latest Stock Analysis on Health Catalyst

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Visionary Wealth Advisors purchased a new position in shares of Health Catalyst in the 2nd quarter worth about $27,000. Hsbc Holdings PLC increased its stake in shares of Health Catalyst by 21.3% during the 1st quarter. Hsbc Holdings PLC now owns 98,868 shares of the company’s stock worth $123,000 after purchasing an additional 17,332 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of Health Catalyst during the 2nd quarter worth approximately $38,000. Williams & Novak LLC raised its stake in shares of Health Catalyst by 56.9% in the second quarter. Williams & Novak LLC now owns 53,607 shares of the company’s stock valued at $107,000 after buying an additional 19,442 shares during the period. Finally, Deutsche Bank AG bought a new stake in shares of Health Catalyst in the second quarter valued at $43,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

(Get Free Report)

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company’s offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.

Read More

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.